

SODIUM CHLORIDE- sodium chloride injection

Liebel-Flarsheim Company LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use Sodium Chloride Injection USP 0.9% safely and effectively. See full prescribing information for Sodium Chloride Injection USP 0.9%.

Sodium Chloride Injection USP 0.9% Prefilled Syringes, For Intravascular Use Only
Initial U.S. Approval: 2006

INDICATIONS AND USAGE

- For use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices (1)

DOSAGE AND ADMINISTRATION

- For single patient use only. (2)
- Determine the volume of flush based on the imaging procedure, location of the vascular access device, length of tubing between power injector and vascular access device, and the contrast agent package insert. (2)
- Individualize the volume of flush based on body weight, fluid status and concomitant medical conditions. (2)
- Typical flush volumes for adults are 10 to 25 mL per injection at rates not to exceed 10 mL/sec. (2)
- May be used for additional infusion to maintain the patency of vascular access at a typical infusion rate of 0.5 to 1 mL per minute. (2)
- Do not use if packaging is damaged, wet, or not intact, if syringe or its tip cap shows signs of damage, leakage or displacement. Do not use if solution is hazy, cloudy, discolored, or contains particulate matter. (2)
- Use aseptic technique. (2)
- Expel residual air from the syringe and tubing prior to connection with the patient's vascular access. (2)

DOSAGE FORMS AND STRENGTHS

- Supplied as a clear, colorless, odorless, sterile solution of Sodium Chloride 0.9% for intravenous administration (3)
- Supplied in 125 mL prefilled syringes (3)

CONTRAINDICATIONS

- None (4)

WARNINGS AND PRECAUTIONS

- Remove all air from the syringe and associated tubing prior to injection. (5.1)
- May cause fluid overload in patients with congestive heart failure, severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia. (5.3)
- Establish intravascular catheter patency prior to administration. (5.4)

ADVERSE REACTIONS

- Adverse reactions due to solution or administration technique may include: air embolism with stroke, chest pain, and dyspnea, arrhythmia, hypotension, myocardial infarction, sepsis, febrile response, local tenderness, infection at the site of injection, venous thrombosis or phlebitis extending from injection site, extravasation, fluid overload and hypervolemia. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Liebel-Flarsheim Company LLC at 1-855-266-5037 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

- Pregnancy: It is not known whether Sodium Chloride Injection USP 0.9% can cause fetal harm. (8.1)
- Pediatrics: Safety and effectiveness have not been established in pediatric patients. (8.4)

- Geriatrics: Dosing for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (8.5)

Revised: 9/2019

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

2.1 Drug Handling

2.2 125 mL Syringe Assembly and Inspection

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Air Embolism

5.2 Infectious Complications

5.3 Fluid Overload

5.4 Extravasation

6 ADVERSE REACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

16 HOW SUPPLIED/STORAGE AND HANDLING

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

- 125 mL Syringe: Sodium Chloride Injection USP 0.9% is indicated for use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following Liebel-Flarsheim power injectors: Angiomat[®], Illumena[®], Illumena[®] Néo, CT9000[®], CT9000[®] ADV, Optistat[®], Optivantage[®] and Optistar Elite.

2 DOSAGE AND ADMINISTRATION

- The 125 mL syringe are for single patient use only.
- Determine the volume of the saline flush for each patient individually based, in part,

on the imaging procedure, the location of the vascular access device, the length of tubing between the Liebel-Flarsheim contrast agent power injector and the vascular access device and the recommendations made on the package insert for the contrast agent. Typical Sodium Chloride Injection USP 0.9% flush volumes following contrast agent administration in adults are 10 to 25 mL per injection at rates not to exceed 10 mL/sec.

- Use of some Liebel-Flarsheim contrast agent power injectors allows for additional infusion of Sodium Chloride Injection USP 0.9% to maintain the patency of vascular access. Typical infusion rates used for this purpose are in the range of 0.5 to 1 mL per minute.
- Individualize infusion rates and flush volumes for each patient based on their body weight, fluid status and concomitant medical conditions.
- Consult the Liebel-Flarsheim contrast agent power injector manual for proper use.


2.1 Drug Handling

- Inspect the syringe for signs of break in sterility.
- Do not use if the syringe or its tip cap shows signs of damage, leakage or displacement.
- Do not use if the solution is hazy, cloudy, discolored or contains particulate matter.
- Use aseptic technique.
- Expel residual air in both the syringe and tubing prior to connection with the patient's vascular access.
- Instructions for assembly and inspection of the Sodium Chloride Injection USP 0.9% syringes prior to use are printed on this sheet.


2.2 125 mL Syringe Assembly and Inspection

NOTE: Exterior of syringe is not sterile.

Contents of syringe and area **under tip cap and piston ribs are sterile** and should be treated accordingly.





Remove syringe from carton and inspect the area around the **tip cap** and outside of **piston** for signs of leakage. Do not use if leakage is observed. Load syringe into power injector.




To remove tip cap from syringe, push in and twist off, then discard. The area under the cap is sterile. Caution should now be used when handling.

Luer Locknut Detail:



Next remove cap from luer locknut dust cover by twisting to break tamper evident seal. Discard cap.



Attach luer locknut to syringe by holding dust cover and screwing to the stop.

Remove and discard dust cover when ready to attach sterile connector tubing.

3 DOSAGE FORMS AND STRENGTHS

Sodium Chloride Injection USP (0.9%)

- a clear, colorless, odorless solution
- supplied in 125 mL prefilled syringes
- contents are sterile

4 CONTRAINDICATIONS

None

5 WARNINGS AND PRECAUTIONS

5.1 Air Embolism

Remove all air from the syringe and associated tubing prior to injection to avoid air embolus with the associated risk of stroke, organ ischemia and/or infarction, and death.

5.2 Infectious Complications

Use of a damaged syringe or failure to maintain aseptic technique may result in infection, sepsis and death [see *Dosage and Administration (2)*].

5.3 Fluid Overload

Sodium Chloride Injection USP 0.9% may cause fluid overload in patients with congestive heart failure, severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia.

Consider each patient's age, body weight, fluid status, concomitant medical conditions and planned radiological procedure to determine if use of Sodium Chloride Injection USP 0.9% is appropriate.

5.4 Extravasation

Extravasation of the Sodium Chloride Injection USP 0.9% may cause mechanical compression of neurovascular structures. Extravasation of contrast agent may result in tissue injury by osmolar and direct cytotoxicity (see package inserts of specific contrast agents). Establish intravascular catheter patency prior to the administration of Sodium Chloride Injection USP 0.9%.

6 ADVERSE REACTIONS

Reported adverse reactions include:

- air embolization with stroke, chest pain, and dyspnea
- arrhythmia
- hypotension
- myocardial infarction
- sepsis
- febrile response
- local tenderness
- infection at the site of injection
- venous thrombosis or phlebitis extending from injection site
- extravasation
- fluid overload
- hypervolemia

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Administration of Sodium Chloride Injection USP 0.9% is not known to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Chloride Injection USP 0.9%.

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation

Risk Summary

Appropriate administration of Sodium Chloride Injection USP 0.9% is not known to cause harm to a breastfed infant.

8.4 Pediatric Use

Safety and effectiveness of Sodium Chloride Injection USP 0.9% administered by power injection in pediatric patients have not been established. Administration of Sodium Chloride Injection USP 0.9% to pediatric patients by power injection is not recommended. When performing manual injection of Sodium Chloride Injection USP 0.9% to pediatric patients, take into account the patient's weight, fluid status, and concomitant medical conditions to determine if use of Sodium Chloride Injection USP 0.9% is appropriate.

The safety of manual injection of Sodium Chloride Injection USP 0.9% in pediatric patients is supported by reported clinical experience with intravenous infusion and flush of sodium chloride injection in pediatric patients.

To minimize the risk of fluid overload, use the smallest dose of Sodium Chloride Injection USP 0.9% necessary for manually flushing contrast agent through the vascular access line.

8.5 Geriatric Use

No clinical studies of Sodium Chloride Injection USP 0.9% were conducted. Other reported clinical experience with sodium chloride injection has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

10 OVERDOSAGE

Use of Sodium Chloride Injection USP 0.9% may pose a threat of overdose marked by electrolyte disturbance and/or fluid overload, particularly in pediatric patients and patients with compromised renal or cardiac function. In the event of overdose, discontinue the infusion, reevaluate the patient and institute appropriate corrective action.

11 DESCRIPTION

Sodium Chloride Injection USP 0.9% is a formulation of sodium chloride in Water for Intravascular Injection. No preservative, antimicrobial agent or buffer is added. Sodium Chloride Injection USP 0.9% is provided as a sterile, nonpyrogenic, clear, colorless, odorless solution.

Molecular formula = NaCl

MW = 58.44

Each mL of Sodium Chloride Injection USP 0.9% contains 9 mg of sodium chloride. The pH is 4.5 to 7.0. The osmolarity is 308 mOsm/L (calc.).

Sodium Chloride Injection USP 0.9% is provided in a 125 mL syringe with a 125 mL fill. The syringes are for single patient use and are disposable and not meant for reuse.

12 CLINICAL PHARMACOLOGY

Sodium Chloride Injection USP 0.9% has an osmotic pressure similar to plasma.

16 HOW SUPPLIED/STORAGE AND HANDLING

Sodium Chloride Injection USP 0.9% is a clear, colorless, odorless solution containing 9 mg/mL of sodium chloride. Sodium Chloride Injection USP 0.9% is supplied in 125 mL prefilled syringes containing 125 mL of solution. Each syringe is sealed with rubber closures and the contents are sterile. The 125 mL syringe is supplied with a luer locknut adapter which is cleared for manufacture and distribution as a device under 510(K) number 862653. The syringes are contained in shipping cartons with the following configurations:

Volume	Packaging	NDC
125 mL	20 syringes per	0019-1188-

in plastic syringes	carton	81
125 mL in plastic RFID-Tagged Syringes*	20 syringes per carton	0019-1188- 27

***Radio Frequency Identification (RFID)**

Technology

RFID-Tagged Syringe Description

This information is for Ultraject® syringes containing Sodium Chloride Injection USP 0.9% that has been labeled with a Radio Frequency Identification (RFID) tag. When used with an RFID-enabled Optivantage Injector, this tag allows for the exchange of product information such as lot number, expiration, concentration, and identification of the syringe as being unused prior to use and used after product administration. Patient information is not utilized in any form with this RFID technology. Sodium Chloride Injection USP 0.9% product quality is not impacted with the use of this RFID tag. Sodium Chloride Injection USP 0.9% RFID syringes require no special handling and should be stored at the conditions listed for the drug product.

RFID-Tagged Syringe Directions for Use

For the RFID technology to function, the syringe must be used with an Optivantage Injector with RFID technology. Function of the RFID technology is not dependent on syringe orientation as it is placed in the injector. Instructions for use of the injector are provided on the injector interface screens and operator’s manual.

If the RFID tag is damaged or otherwise non-functional, the injector will notify the user. Should this occur, the Sodium Chloride Injection USP 0.9% syringe with the non-functional RFID tag may still be used but no data will be transferred to the injector.

Regarding interference with medical devices, the RFID tag and injector system meet the IEC 60601-1-2 requirements for emission and immunity standards for medical devices. Follow all manufacturers’ guidelines and do not operate any part of the Optivantage Injector System and RFID-tagged syringes within 6 inches (15 cm) of a pacemaker and/or defibrillator.

Storage

Store Sodium Chloride Injection USP 0.9% syringes and RFID-tagged syringes at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

PROTECT FROM FREEZING

Manufactured by:
Lieber-Flarsheim Company LLC
Raleigh, NC 27616

Made in USA

GBT 11880919

Issued: 9/19

Guerbet

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 125 mL Syringe

For Intravascular Use

Sterile Solution

NDC 0019-1188-81

125 mL

Sodium Chloride Injection USP 0.9%

MEDICATION AND FLUID PATHWAY ARE STERILE.
OUTSIDE OF SYRINGE IS NOT STERILE.

**SINGLE DOSE UNIT, DISCARD UNUSED PORTION.
EXPEL AIR BEFORE USE.
PROTECT FROM FREEZING.**

Rx only

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Each mL contains 9 mg sodium chloride.

Dosage: See package insert.

Discard if syringe seal is broken or leakage is observed.

Manufactured by: Liebel-Flarsheim Company LLC
Raleigh, NC 27616
Made in USA

Guerbet

12070916

For Intravascular Use
Sterile Solution

NDC 0019-1188-81

125 mL

Sodium Chloride Injection USP 0.9%

MEDICATION AND FLUID PATHWAY
ARE STERILE.

OUTSIDE OF SYRINGE IS NOT STERILE.

**SINGLE DOSE UNIT, DISCARD UNUSED
PORTION.**

EXPEL AIR BEFORE USE.

Rx only

PROTECT FROM FREEZING.

Store at 25°C (77°F); excursions permitted
to 15° to 30°C (59° to 86°F)

[see USP Controlled Room Temperature].

Each mL contains 9 mg sodium chloride.

Dosage: See package insert.

**Discard if syringe seal is broken or
leakage is observed.**

Manufactured by:

Liebel-Flarshheim Company LLC

Raleigh, NC 27616


Made in USA

Guerbet | 



12070916





SODIUM CHLORIDE

sodium chloride injection

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0019-1188
Route of Administration	INTRAVASCULAR		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37)	SODIUM CHLORIDE	.9 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0019-1188-81	20 in 1 CARTON	09/01/2012	
1		1 in 1 BOX		
1		125 mL in 1 SYRINGE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
2	NDC:0019-1188-27	20 in 1 CARTON	09/01/2012	
2		1 in 1 BOX		
2		125 mL in 1 SYRINGE, PLASTIC; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA021569	09/01/2012	

Labeler - Liebel-Flarsheim Company LLC (057880002)

Establishment

Name	Address	ID/FEI	Business Operations
Avantor Performance Materials, Inc.		152791026	API MANUFACTURE(0019-1188)

Establishment

Name	Address	ID/FEI	Business Operations
LIEBEL-FLARSHEIM COMPANY LLC		109024984	ANALYSIS(0019-1188) , MANUFACTURE(0019-1188)

Revised: 12/2022

Liebel-Flarsheim Company LLC